579 related articles for article (PubMed ID: 19122266)
1. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Fukunaga M
Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Miki T; Minamide T
Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
[TBL] [Abstract][Full Text] [Related]
3. [Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Chatani Y
Clin Calcium; 2005 Jan; 15(1):9-14. PubMed ID: 15632466
[TBL] [Abstract][Full Text] [Related]
4. [Progress in the treatment of osteoporosis].
Sugimoto T
Rinsho Byori; 2008 Oct; 56(10):887-93. PubMed ID: 19068785
[TBL] [Abstract][Full Text] [Related]
5. [Biochemical markers of bone turnover. New aspect. Biochemical bone markers of bone in patients treated with glucocorticoid].
Yamauchi M
Clin Calcium; 2009 Aug; 19(8):1092-1100. PubMed ID: 19638692
[TBL] [Abstract][Full Text] [Related]
6. [New development in bisphosphonate treatment. Bisphosphonates for the treatment of glucocorticoid-induced osteoporosis].
Soen S
Clin Calcium; 2009 Jan; 19(1):44-53. PubMed ID: 19122264
[TBL] [Abstract][Full Text] [Related]
7. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
[TBL] [Abstract][Full Text] [Related]
8. Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Tanaka M; Mori H; Kayasuga R; Ochi Y; Kawada N; Yamada H; Kishikawa K
Bone; 2008 Nov; 43(5):894-900. PubMed ID: 18687415
[TBL] [Abstract][Full Text] [Related]
9. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.
Mori H; Tanaka M; Kayasuga R; Masuda T; Ochi Y; Yamada H; Kishikawa K; Ito M; Nakamura T
Bone; 2008 Nov; 43(5):840-8. PubMed ID: 18718565
[TBL] [Abstract][Full Text] [Related]
10. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
11. A review of minodronic acid hydrate for the treatment of osteoporosis.
Tanishima S; Morio Y
Clin Interv Aging; 2013; 8():185-9. PubMed ID: 23440003
[TBL] [Abstract][Full Text] [Related]
12. [Treatment and management of severe osteoporosis].
Okano T; Hagino H
Clin Calcium; 2006 Sep; 16(9):1451-56. PubMed ID: 16951467
[TBL] [Abstract][Full Text] [Related]
13. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Odvina CV; Levy S; Rao S; Zerwekh JE; Rao DS
Clin Endocrinol (Oxf); 2010 Feb; 72(2):161-8. PubMed ID: 19302584
[TBL] [Abstract][Full Text] [Related]
14. [Measurement of bone mineral density is necessary for monitoring of bisphosphonate treatment].
Soen S
Clin Calcium; 2011 Jan; 21(1):116-9. PubMed ID: 21187604
[TBL] [Abstract][Full Text] [Related]
15. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.
Yamagami Y; Mashiba T; Iwata K; Tanaka M; Nozaki K; Yamamoto T
Bone; 2013 May; 54(1):1-7. PubMed ID: 23356990
[TBL] [Abstract][Full Text] [Related]
16. [Long-term bisphosphonate administration and its effect on bone metabolism].
Hagino H
Clin Calcium; 2005 Apr; 15(4):643-7. PubMed ID: 15802778
[TBL] [Abstract][Full Text] [Related]
17. [When should bisphosphonate treatment be discontinued?].
Eriksen EF; Halse J
Tidsskr Nor Laegeforen; 2012 Aug; 132(14):1630-2. PubMed ID: 22875131
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis.
Kitamura N; Shiraiwa H; Inomata H; Nozaki T; Ikumi N; Sugiyama K; Nagasawa Y; Karasawa H; Iwata M; Matsukawa Y; Takei M
Int J Rheum Dis; 2018 Apr; 21(4):813-820. PubMed ID: 26929019
[TBL] [Abstract][Full Text] [Related]
19. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
Takata S
Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
[No Abstract] [Full Text] [Related]
20. [New therapy using bisphosphonate for urolithiasis].
Yasui T; Niimi K; Hirose M
Clin Calcium; 2011 Oct; 21(10):1511-5. PubMed ID: 21960237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]